華熙生物(688363.SH):聘任趙燕擔任公司總經理
格隆匯6月11日丨華熙生物(688363.SH)公佈,公司於2025年6月11日召開第三屆董事會第一次會議,審議通過了《關於聘任公司總經理的議案》及《關於聘任公司副總經理、董事會祕書及財務總監的議案》,聘任趙燕女士擔任公司總經理,聘任郭珈均先生、李亦爭先生、汪卉先生、相茂功先生為公司副總經理,其中李亦爭先生兼任公司董事會祕書、汪卉先生兼任公司財務總監,任期自本次董事會審議通過之日至第三屆董事會任期屆滿之日。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.